INM
InMed Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$1.37
+3.44%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.35
From 52W high−36.79%
Volume38467.00
Market cap$7.50M
P/E (TTM)—
P/S (TTM)0.0x
Div yield—
Key dataOct 19, 2026
Open
$1.35
From 52W high
−36.79%
Volume
38467.00
Market cap
$7.50M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
P/E (TTM)
—
RSI (14)
53.9
MomentumView details →
1D Return
+3.44%
YTD Return
+29.72%
SummaryUpdated Jun 1, 2026
InMed Pharmaceuticals Inc. (NASDAQ:INM) is a clinical-stage pharmaceutical company founded in 1981 and headquartered in Vancouver, Canada. Originally incorporated as Cannabis Technologies Inc., the company changed its name to InMed Pharmaceuticals in October 2014 and went public in May 2014. InMed focuses on developing cannabinoid-based therapies for rare diseases and has evolved from early-stage research into clinical trials, with its lead product candidate currently in Phase 2 clinical development for a rare skin condition.
Similar companies
Latest newsMore news →
InMed Pharmaceuticals Inc. received a NASDAQ notice dated September 16, 2026 for failing to comply with the minimum shareholders' equity requirement under Rule 5550(b)(1), and intends to submit a compliance plan by November 2, 2026.31d agoInMed Pharmaceuticals reported its financial results for the fiscal year ended June 30, 2026.40d ago